Nautilus Biotechnology (NAUT) Other financing activities (2020 - 2026)
Nautilus Biotechnology (NAUT) posted Other financing activities of $102000.0 for Q2 2026, down 90.77% sequentially from $1.1 million in Q1 2026, and up 47.83% YoY from $69000.0 in Q2 2025.
Nautilus Biotechnology (NAUT) Other financing activities (2020 - 2026) Analysis & Trends
Nautilus Biotechnology has reported Other financing activities for 7 years, with the latest figure at $102000.0 in Q2 2026.
- Quarterly Other financing activities rose 47.83% year-over-year to $102000.0 in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.3 million (up 205.26% YoY) and the FY2025 annual result came in at $156000.0, down 74.84% from the prior year.
- Other financing activities declined to $102000.0 in Q2 2026 per NAUT's latest filing, from $1.1 million in the prior quarter.
- Over five years, Other financing activities peaked at $1.1 million in Q1 2026 and troughed at $1000.0 in Q1 2023.
- A 5-year average of $161062.5 and a median of $88500.0 in 2022 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2023 and 2024: Other financing activities slumped 99.36% in 2023, then surged 24400.0% in 2024.
- Over 5 years, Other financing activities stood at $56000.0 in 2022, then surged by 207.14% to $172000.0 in 2023, then rose by 19.19% to $205000.0 in 2024, then sank by 66.34% to $69000.0 in 2025, then jumped by 47.83% to $102000.0 in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered $102000.0, $1.1 million, and $69000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Nautilus Biotechnology | 120.16 Mn | 120.16 Mn | 175,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 102,000.00 |
| Jun 30, 2026 | 102,000.00 |
| Mar 31, 2026 | 1.11 Mn |
| Mar 31, 2026 | 1.11 Mn |
| Dec 31, 2025 | 69,000.00 |
| Dec 31, 2025 | 69,000.00 |
| Jun 30, 2025 | 69,000.00 |
| Jun 30, 2025 | 69,000.00 |
| Mar 31, 2025 | 18,000.00 |
| Mar 31, 2025 | 18,000.00 |
| Dec 31, 2024 | 205,000.00 |
| Dec 31, 2024 | 205,000.00 |
| Sep 30, 2024 | 126,000.00 |
| Sep 30, 2024 | 126,000.00 |
| Jun 30, 2024 | 44,000.00 |
| Jun 30, 2024 | 44,000.00 |
| Mar 31, 2024 | 245,000.00 |
| Mar 31, 2024 | 245,000.00 |
| Dec 31, 2023 | 172,000.00 |
| Dec 31, 2023 | 172,000.00 |